Biogen Inc. (BIIB) Dividend History

Company News

• Multiple Sclerosis Clinical Trial Pipeline Shows Potential with Active Contributions from 60+ Key Companies | DelveInsight

  The multiple sclerosis market is experiencing significant growth due to the rising prevalence of the disease, driving investment in research and development for effective treatments. The pipeline shows promise with over 60 active companies working on 75+ pipeline treatments, including promising drug candidates targeting novel mechanisms.

  GlobeNewswire Inc.

  Featured Companies: BMY
• Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact

  Biogen reported strong Q1 2025 earnings, with EPS of $3.02 beating estimates. Revenue rose 6% to $2.43 billion, driven by growth in rare disease drugs Spinraza and Skyclarys. The company lowered its full-year 2025 EPS guidance but expects to avoid significant tariff impact.

  Benzinga
• Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025

  Eli Lilly's Kisunla, its Alzheimer's disease treatment, represents a significant growth opportunity for the company as the global Alzheimer's market is expected to grow rapidly. Lilly's valuation has compressed, presenting a compelling opportunity for investors.

  The Motley Fool
• These Battered S&P 500 Stocks Could Be Ripe for a Turnaround in 2025

  Several S&P 500 stocks posted sharp declines in 2024, despite a generally bullish year for the index. These battered stocks could be ripe for a turnaround in 2025, as investors look for undervalued gems in the market.

  Investing.com

  Featured Companies: CVS DVN SLB TFX
• Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised

  Biogen reported strong Q2 results, beating earnings and revenue estimates. The company raised its 2024 guidance, driven by growth in new products like Leqembi and Skyclarys, offsetting declines in key multiple sclerosis drugs. However, the termination of a program with Denali Therapeutics weighed on the stock.

  Zacks Investment Research

  Featured Companies: DNLI MRNA SAGE